- Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company focused on developing cell therapies, particularly Deramiocel for Duchenne muscular dystrophy.
- Despite legal challenges, analyst Madison El-Saadi of B.Riley Financial has issued a "Buy" rating for Capricor Therapeutics with a price target of $21.00, indicating a potential upside of approximately 49.1%.
- Capricor Therapeutics is currently facing class-action lawsuits alleging securities fraud and misleading investors regarding the FDA approval pathway for Deramiocel.
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company that focuses on developing cell therapies. Its main product candidate is Deramiocel, which is designed to treat heart and skeletal muscle issues related to Duchenne muscular dystrophy. The company operates in a high-stakes industry where clinical trial results and regulatory decisions can greatly impact its value.
Despite recent challenges, analyst Madison El-Saadi of B.Riley Financial has set a "Buy" rating for CAPR. The report, published by StreetInsider, includes a price target of $21.00. This suggests a potential upside of approximately 49.1% from the stock's price of $8.37 at the time the target was set on September 14, 2026.
However, this positive outlook contrasts with the company's current legal issues. CAPR is facing a class-action lawsuit filed by the law firm Bronstein, Gewirtz & Grossman, LLC. A class-action lawsuit is a legal case where one or several people sue on behalf of a larger group. The lawsuit alleges securities fraud violations against the company.
The legal action, also initiated by Robbins LLP, follows a significant 64% drop in CAPR's stock price. The complaint claims that Capricor misled investors about the path to FDA approval for Deramiocel between December 17, 2025, and July 26, 2026, as highlighted by GlobeNewsWire. The company's stock has a 52-week range between $2.96 and $40.37.
